Fact checked by Nick Blackmer Zunveyl (benzgalantamine)—a better-tolerated version of the Alzheimer’s drug Razadyne ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

New research suggests that the risk for developing dementia is significantly higher than previously estimated, and the burden ...

Firms developing Alzheimer’s drugs have already seen big peaks and troughs. Biogen shares soared 44% on a single day in November 2020 after news that an experimental drug appeared to be ...

This has demonstrated the potential of palbociclib in treating Alzheimer’s disease,” Chen said. The research shows the drug ...

The doctor said his pulse rate is low, and the medications have a tendency to lower the pulse even more, which can be dangerous. His Alzheimer's stage is 4-5, and his MMSE score was 5 out of 30. Is ...

In a mouse study, researchers found that zolpidem (Ambien), a common sleep aid, could prevent the brain from effectively ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.

FDA sets August 31, 2025, as the action date for Eisai and Biogen's Leqembi subcutaneous autoinjector application. Leqembi's ...